NCT00284934View on ClinicalTrials.gov

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Kidney Diseases
Interventions
DRUG

Enteric-coated mycophenolate sodium (EC-MPS)

DRUG

Tacrolimus

DRUG

Corticosteroids

At a dose of at least 5 mg/day.

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00284934 - Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter